HMGB1 and neoplasm: Apetoh et al. further demonstrated that HMGB1 released from oxaliplatin-treated dying tumor cells binds to TLR4 on dendritic cells and is required for cross-presentation of tumor antigens and a subsequent effective anti-tumor immune response.